Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them

被引:55
作者
Peters, Sheila Annie [1 ]
Dolgos, Hugues [1 ]
机构
[1] Merck Healthcare KGaA, Frankfurter Str 250, D-64293 Darmstadt, Germany
关键词
DRUG-DRUG INTERACTION; SIMULATION; PREDICTION; IDENTIFICATION; VARIABILITY; CLOPIDOGREL; CRIZOTINIB; DISCOVERY; EVALUATE;
D O I
10.1007/s40262-019-00790-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
When scientifically well-founded, the mechanistic basis of physiologically based pharmacokinetic (PBPK) models can help reduce the uncertainty and increase confidence in extrapolations outside the studied scenarios or studied populations. However, it is not always possible to establish mechanistically credible PBPK models. Requirements to establishing confidence in PBPK models, and challenges to meeting these requirements, are presented in this article. Parameter non-identifiability is the most challenging among the barriers to establishing confidence in PBPK models. Using case examples of small molecule drugs, this article examines the use of hypothesis testing to overcome parameter non-identifiability issues, with the objective of enhancing confidence in the mechanistic basis of PBPK models and thereby improving the quality of predictions that are meant for internal decisions and regulatory submissions. When the mechanistic basis of a PBPK model cannot be established, we propose the use of simpler models or evidence-based approaches.
引用
收藏
页码:1355 / 1371
页数:17
相关论文
共 44 条
  • [1] Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations
    Abduljalil, Khaled
    Cain, Theresa
    Humphries, Helen
    Rostami-Hodjegan, Amin
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (09) : 1478 - 1484
  • [2] [Anonymous], 2012, Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical Industry
  • [3] [Anonymous], 2018, PHYSL BASED PHARMACO
  • [4] Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective
    Arya, V.
    Zhao, P.
    Reynolds, K. S.
    Mishra, P.
    Younis, I. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (04) : 578 - 580
  • [5] Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example
    Chen, Yuan
    Zhu, Rui
    Ma, Fang
    Mao, Jialin
    Chen, Eugene C.
    Choo, Edna F.
    Sahasranaman, Srikumar
    Liu, Lichuan
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (09) : 420 - 430
  • [6] Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
    Cubitt, Helen E.
    Yeo, Karen R.
    Howgate, Eleanor M.
    Rostami-Hodjegan, Amin
    Barter, Zoe E.
    [J]. XENOBIOTICA, 2011, 41 (08) : 623 - 638
  • [7] Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface
    Dodd, Stephanie
    Kollipara, Sivacharan
    Sanchez-Felix, Manuel
    Kim, Hyungchul
    Meng, Qingshuo
    Beato, Stefania
    Heimbach, Tycho
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 87 - 101
  • [8] Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
    Einolf, Heidi J.
    Lin, Wen
    Won, Christina S.
    Wang, Lai
    Gu, Helen
    Chun, Dung Y.
    He, Handan
    Mangold, James B.
    [J]. DRUG METABOLISM AND DISPOSITION, 2017, 45 (12) : 1304 - 1316
  • [9] European Medicines Agency, EUR FED PHARM IND AS
  • [10] European Medicines Agency, 2018, Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation